Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition)

doi:10.19401/j.cnki.1007-3639.2022.08.010

Abstract

Abstract:

Recently, new strategies for the integrated treatment of gynecological malignancies have been improved along with the development of reproductive oncology and hereditary tumors concepts. The traditional “single-disciplinary treatment” mode is difﬁcult to optimally solve the diagnosis and treatment problems of patients. The application of multidisciplinary team (MDT) can provide the most scientiﬁc and reasonable diagnosis and treatment plan for patients and reﬁne the existing therapies to improve the efﬁcacy and quality of medical treatment. Based on the most recent advances and clinical practice experience in MDT of gynecological malignancies, The Society of Gynecological Cancer of China Anti-Cancer Association organized multidisciplinary experts in gynecologic oncology and related area to formulate “Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition)”, in order to improve the understanding of MDT among Chinese gynecologic oncologists and further standardize the application of MDT in gynecological malignancies.

Key words: Gynecology, Tumor, Multidisciplinary team, Consensus

CLC Number:

R737.3

The Society of Gynecological Cancer of China Anti-Cancer Association, Multidisciplinary Diagnosis and Treatment (MDT) Committee of China Anti-Cancer Association, Multidisciplinary Cancer Diagnosis and Treatment Committee of Chinese Medical Doctor Association. Consensus of Chinese experts on multidisciplinary team of gynecological malignant tumors (2022 edition)[J]. China Oncology, 2022, 32(8): 747-756.

Figures/Tables 3

References 42

[1]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	LAMB B W, SEVDALIS N, TAYLOR C, et al. Multidisciplinary team working across different tumour types: analysis of a national survey[J]. Ann Oncol, 2012, 23(5): 1293-1300. doi: 10.1093/annonc/mdr453
[3]	TABERNA M, GIL MONCAYO F, JANÉ-SALAS E, et al. The multidisciplinary team (MDT) approach and quality of care[J]. Front Oncol, 2020, 10: 85. doi: 10.3389/fonc.2020.00085
[4]	FALZONE L, SCANDURRA G, LOMBARDO V, et al. A multidisciplinary approach remains the best strategy to improve and strengthen the management of ovarian cancer (review)[J]. Int J Oncol, 2021, 59(1): 53. doi: 10.3892/ijo.2021.5233
[5]	BAERT T, FERRERO A, SEHOULI J, et al. The systemic treatment of recurrent ovarian cancer revisited[J]. Ann Oncol, 2021, 32(6): 710-725. doi: 10.1016/j.annonc.2021.02.015
[6]	TAYLOR C, SHEWBRIDGE A, HARRIS J, et al. Benefits of multidisciplinary teamwork in the management of breast cancer[J]. Breast Cancer (Dove Med Press), 2013, 5: 79-85.
[7]	LICITRA L, KEILHOLZ U, TAHARA M, et al. Evaluation of the benefit and use of multidisciplinary teams in the treatment of head and neck cancer[J]. Oral Oncol, 2016, 59: 73-79. doi: 10.1016/j.oraloncology.2016.06.002
[8]	ELNAHAL S M, PRONOVOST P J, HERMAN J M. More than the sum of its parts: how multidisciplinary cancer care can benefit patients, providers, and health systems[J]. J Natl Compr Canc Netw, 2013, 11(6): 738-742. doi: 10.6004/jnccn.2013.0090
[9]	HUNG H Y, TSENG Y H, CHAO H S, et al. Multidisciplinary team discussion results in survival benefit for patients with stage Ⅲ non-small cell lung cancer[J]. PLoS One, 2020, 15(10): e0236503.
[10]	KHALAFALLAH A M, JIMENEZ A E, ROMO C G, et al. Quantifying the utility of a multidisciplinary neuro-oncology tumor board[J]. J Neurosurg, 2020: 1-6.
[11]	PRABHAKAR C N, FONG K M, PEAKE M D, et al. The effectiveness of lung cancer MDT and the role of respiratory physicians[J]. Respirology, 2015, 20(6): 884-888. doi: 10.1111/resp.12520
[12]	HAWARD R A. The Calman-Hine report: a personal retrospective on the UK’s first comprehensive policy on cancer services[J]. Lancet Oncol, 2006, 7(4): 336-346. doi: 10.1016/S1470-2045(06)70659-3
[13]	JUNOR E J, HOLE D J, GILLIS C R. Management of ovarian cancer: referral to a multidisciplinary team matters[J]. Br J Cancer, 1994, 70(2): 363-370. doi: 10.1038/bjc.1994.307
[14]	COHEN P, TAN A L, PENMAN A. The multidisciplinary tumor conference in gynecologic oncology: does it alter management?[J]. Int J Gynecol Cancer, 2009, 19(9): 1470-1472. doi: 10.1111/IGC.0b013e3181bf82df
[15]	CARLSON J W, STOJADINOVIC A, ENNIS W, et al. Multidisciplinary panel discussion of a gynecologic oncology patient: preventing wound complications[J]. Gynecol Oncol, 2008, 111(2 Suppl): S98-S100.
[16]	PILLAY B, WOOTTEN A C, CROWE H, et al. The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: a systematic review of the literature[J]. Cancer Treat Rev, 2016, 42: 56-72. doi: 10.1016/j.ctrv.2015.11.007
[17]	ALETTI G D, GARBI A, MESSORI P, et al. Multidisciplinary approach in the management of advanced ovarian cancer patients: a personalized approach. Results from a specialized ovarian cancer unit[J]. Gynecol Oncol, 2017, 144(3): 468-473. doi: 10.1016/j.ygyno.2017.01.017
[18]	SCOTT R, HAWARDEN A, RUSSELL B, et al. Decision-making in gynaecological oncology multidisciplinary team meetings: a cross-sectional, observational study of ovarian cancer cases[J]. Oncol Res Treat, 2020, 43(3): 70-77. doi: 10.1159/000504260
[19]	SELBY P, POPESCU R, LAWLER M, et al. The value and future developments of multidisciplinary team cancer care[J]. Am Soc Clin Oncol Educ Book, 2019, 39: 332-340.
[20]	SPECCHIA M L, FRISICALE E M, CARINI E, et al. The impact of tumor board on cancer care: evidence from an umbrella review[J]. BMC Health Serv Res, 2020, 20(1): 73. doi: 10.1186/s12913-020-4930-3
[21]	FUNG-KEE-FUNG M, KENNEDY E B, BIAGI J, et al. An organizational guideline for gynecologic oncology services[J]. Int J Gynecol Cancer, 2015, 25(4): 551-558. doi: 10.1097/IGC.0000000000000400
[22]	RAUSEI S, UCCELLA S, D’ALESSANDRO V, et al. Aggressive surgery for advanced ovarian cancer performed by a multidisciplinary team: a retrospective analysis on a large series of patients[J]. Surg Open Sci, 2019, 1(1): 43-47. doi: 10.1016/j.sopen.2019.05.005
[23]	EL SAGHIR N S, CHARARA R N, KREIDIEH F Y, et al. Global practice and efficiency of multidisciplinary tumor boards: results of an American Society of Clinical Oncology international survey[J]. J Glob Oncol, 2015, 1(2): 57-64.
[24]	中国医师协会神经外科医师分会脑胶质瘤专业委员会. 胶质瘤多学科诊治(MDT)中国专家共识[J]. 中华神经外科杂志, 2018, 34(2): 113-118.
	Professional Committee of Brain Glioma, Branch of Neurosurgeons, Chinese Medical Doctor Association. Consensus of Chinese experts on multidisciplinary team (MDT) of brain glioma[J]. Chin J Neurosurg, 2018, 34(2): 113-118.
[25]	JALIL R, LAMB B, RUSS S, et al. The cancer multi-disciplinary team from the coordinators’ perspective: results from a national survey in the UK[J]. BMC Health Serv Res, 2012, 12: 457. doi: 10.1186/1472-6963-12-457
[26]	OSAROGIAGBON R U, FREEMAN R K, KRASNA M J. Implementing effective and sustainable multidisciplinary clinical thoracic oncology programs[J]. Transl Lung Cancer Res, 2015, 4(4): 448-455.
[27]	张建栋, 李梁和, 陈忠胜, 等. 多学科团队协作在中晚期结直肠癌诊疗价值的研究[J]. 贵州医药, 2021, 45(3): 355-358.
	ZHANG J D, LI L H, CHEN Z S, et al. Study on the value of multidisciplinary teamwork in the diagnosis and treatment of advanced colorectal cancer[J]. Guizhou Med J, 2021, 45(3): 355-358.
[28]	中国医师协会妇产科医师分会妇科肿瘤学组. 卵巢恶性肿瘤多学科团队协作诊治的中国专家共识[J]. 中华妇产科杂志, 2021, 56(12): 825-830.
	Gynecological Oncology Group, Branch of Obstetricians and Gynecologists, Chinese Medical Doctor Association. Chinese consensus on multi-disciplinary team treatment of ovarian malignancies[J]. Chin J Obstet Gynecol, 2021, 56(12): 825-830.
[29]	钟文昭, 中国胸部肿瘤研究协作组, 中国抗癌协会肺癌专业委员会, 等. 肺癌多学科团队诊疗中国专家共识[J]. 中华肿瘤杂志, 2020, 42(10): 817-828.
	ZHONG W Z, China Thoracic Cancer Research Collaborative Group, Lung Cancer Committee of Chinese Anti-Cancer Association, et al. Chinses expert consensus on the multidisciplinary team diagnosis and treatment of lung cancer[J]. Chin J Oncol, 2020, 42(10): 817-828.
[30]	叶定伟, 秦晓健, 朱耀, 等. 泌尿男生殖系统肿瘤多学科团队诊治组织与实施规范中国专家共识(2020年版)[J]. 中国癌症杂志, 2020, 30(4): 313-320.
	YE D W, QIN X J, ZHU Y, et al. Consensus of Chinese experts on the organization and implementation of the multidisciplinary team for diagnosis and treatment of genitourinary system tumors (2020 edition)[J]. China Oncol, 2020, 30(4): 313-320.
[31]	HEUDEL P E, DEVOUASSOUX-SHISHEBORAN M, TAIEB S, et al. Multidisciplinary management of advanced ovarian cancer for an optimal therapeutic strategy[J]. Eur J Gynaecol Oncol, 2017, 38(2): 175-180.
[32]	王成锋, 杨尹默, 傅德良, 等. 中国胰腺癌多学科综合治疗模式专家共识(2020版)[J]. 临床肝胆病杂志, 2020, 36(9): 1947-1951.
	WANG C F, YANG Y M, FU D L, et al. Expert consensus on the MDT model of pancreatic cancer in China (2020 version)[J]. J Clin Hepatol, 2020, 36(9): 1947-1951.
[33]	DE FELICE F, TOMBOLINI V, DE VINCENTIIS M, et al. Multidisciplinary team in head and neck cancer: a management model[J]. Med Oncol, 2018, 36(1): 2. doi: 10.1007/s12032-018-1227-z
[34]	QUARANTA M, NATH R, MEHRA G, et al. Surgery of benign ovarian masses by a gynecological cancer surgeon: a cohort study in a tertiary cancer centre[J]. Cureus, 2020, 12(7): e9201.
[35]	TOOKMAN L, KRELL J, NKOLOBE B, et al. Practical guidance for the management of side effects during rucaparib therapy in a multidisciplinary UK setting[J]. Ther Adv Med Oncol, 2020, 12: 1758835920921980.
[36]	RASPOLLINI M R, LAX S F, MCCLUGGAGE W G. The central role of the pathologist in the management of patients with cervical cancer: ESGO/ESTRO/ESP guidelines[J]. Virchows Arch, 2018, 473(1): 45-54. doi: 10.1007/s00428-018-2372-7
[37]	KOH W J, ABU-RUSTUM N R, BEAN S, et al. Cervical cancer, version 3 2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(1): 64-84. doi: 10.6004/jnccn.2019.0001
[38]	MINIG L, PADILLA-ISERTE P, ZORRERO C. The relevance of gynecologic oncologists to provide high-quality of care to women with gynecological cancer[J]. Front Oncol, 2015, 5: 308.
[39]	COLOMBO N, CREUTZBERG C, AMANT F, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up[J]. Radiother Oncol, 2015, 117(3): 559-581. doi: 10.1016/j.radonc.2015.11.013
[40]	SPOOR E, CROSS P. Audit of endometrial cancer pathology for a regional gynecological oncology multidisciplinary meeting[J]. Int J Gynecol Pathol, 2019, 38(6): 514-519. doi: 10.1097/PGP.0000000000000547
[41]	TRIMBLE E L. The NIH consensus conference on ovarian cancer: screening, treatment, and follow-up[J]. Gynecol Oncol, 1994, 55(3 Pt 2): S1-S3.
[42]	NEWTON C, NORDIN A, ROLLAND P, et al. British Gynaecological Cancer Society recommendations and guidance on patient-initiated follow-up (PIFU)[J]. Int J Gynecol Cancer, 2020, 30(5): 695-700. doi: 10.1136/ijgc-2019-001176

×××MDT日志
MDT地点								MDT时间
首席专家								主持人
单位科室								主管医师
参与科室
参与专家
患者基线特征	患者姓名：		住院/门诊号：							MDT次数：
	年龄：		性别：							ECOG评分：
	主诉
	现病史
	月经及婚育
	既往史
	个人史
	家族史
患者临床特征	血压（mmHg）							体温（℃）
	心率（次/分）							呼吸（次/分）
	体格检查
	实验室检查
	影像学诊断
	影像学检查时间（填写检测日期,非报告日期）：
	病理学诊断
	病理学检查时间（填写活检的日期,非报告日期）：
	基因突变检测
	基因检测时间（填写活检的日期,非报告日期）：
	既往治疗&疗效评估
	既往治疗：填写治疗方案开始日期,初始治疗者填写“无”
目前诊断（分期）：
MDT目的/拟讨论问题：
MDT专家意见
各科专家意见
	首席专家意见
	MDT共识及意见
	循证医学证据
	参考指南
参照临床试验
参考文献
执行反馈否全部完成
完全执行			部分执行					未执行
随访信息
随访时间			是否死亡					是 □ 否 □
如果是则死亡日期						死亡原因
肿瘤评价		□ 好转;□ 复发;□ 转移;□ 进展;□ 稳定
复发情况	局部										目前诊断
复发情况	远处										目前诊断
不良反应	≥3级不良反应						发生时间
	1级不良反应
	2级不良反应
	3级不良反应
复发后治疗方式
外科
内科
放疗
疗效评价指标
DFS：月	PFS：月				OS：月				QOL：
是否纳入临床试验
患者是否满足入排标准：				否□				是□
如果“是”请填写入组临床试验注册号